PCM
ARIA

Prelude Capital Management’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Prelude Capital Management’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-8,600
Closed -$64K – 1992
2016
Q2 		$64K Buy
8,600
+7,600
+760% +$57K 0.01% 921
2016
Q1 		$6K Sell
1,000
-9,000
-90% -$50.4K ﹤0.01% 1196
2015
Q4 		$63K Buy
+10,000
New +$65.6K 0.01% 986
2015
Q2 		– Sell
-4,400
Closed -$36K – 2282
2015
Q1 		$36K Sell
4,400
-55,600
-93% -$411K 0.01% 1581
2014
Q4 		$412K Buy
60,000
+59,999
+5,999,900% +$375K 0.06% 371
2014
Q3 		$0 Hold
1
– – ﹤0.01% 2317
2014
Q2 		$0 Hold
1
– – ﹤0.01% 2338
2014
Q1 		$0 Buy
+1
New +$8 ﹤0.01% 2258
2013
Q4 		– Sell
-11,537
Closed -$62.3K – 2121
2013
Q3 		$212K Sell
11,537
-17,420
-60% -$338K 0.03% 526
2013
Q2 		$506K Buy
+28,957
New +$513K 0.11% 249

Other funds holding ARIA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Prelude Capital Management's ARIA Position: Q3 2016 in Review

Prelude Capital Management sold out of Ariad Pharmaceuticals Inc (ARIA) in Q3 2016, closing a stake of 8,600 shares — an estimated $64K sold.

Prelude Capital Management first reported a position in ARIA in Q2 2013 and held it in 10 quarters. The position peaked at $506K in Q2 2013. 202 funds tracked by Wall St. Rank hold ARIA as of Q3 2016.

  • Prelude Capital Management reported no remaining Ariad Pharmaceuticals Inc position as of Q3 2016 after selling out during the quarter.
  • Prelude Capital Management sold 8,600 Ariad Pharmaceuticals Inc shares in Q3 2016, an estimated $64K.
  • Prelude Capital Management first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 10 quarters.
  • Prelude Capital Management's Ariad Pharmaceuticals Inc position peaked at $506K in Q2 2013.
  • 202 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q3 2016.

Based on Prelude Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.